Skip to content
OpenCapital
Get started

Ultragenyx Pharmaceutical RARE Cash ratio

Cash ratio at other companies

Eli Lilly logo
Eli LillyLLY
0.1×0.0×
Amgen logo
AmgenAMGN
0×0.0×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
0.2×-0.8×
Arrowhead Research logo
Arrowhead ResearchARWR
0.6×-0.2×
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
3.1×+1.1×
Moderna logo
ModernaMRNA
0.8×-0.2×

Other financials

Income statement

See full
Revenue$136.0M-2.2%
Operating income-$169.0M-18.2%
Net income-$185.0M-22.5%
EPS (diluted)-$1.84-17.2%

Balance sheet

See full
Cash & equivalents$175.0M+37.8%
Total debt$36.0M-10.8%
Total equity-$236.0M-264%
Total assets$1.3B-1.2%

Cash flow

See full
Operating cash flow-$197.0M-18.7%
CapEx$1.0M0.0%
Free cash flow-$198.0M-18.6%

Valuation

See full
Market cap$2.83B-39.4%
P/S4.2×-3.7×

Profitability

See full
Gross margin97.2%—
Operating margin-83.8%-3.0pp
Net margin-90.9%-2.1pp
FCF margin-75.1%+10.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×—
Current ratio2×-0.4×

Where this comes from

Calculated from Ultragenyx Pharmaceutical’s reported figures.

cash and equivalents/total current liabilities=0.5×

Based on the most recent quarter.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's cash ratio?
Ultragenyx Pharmaceutical (RARE) reported cash ratio of 0.5× in Q1 2026.
How has Ultragenyx Pharmaceutical's cash ratio changed year-over-year?
Ultragenyx Pharmaceutical's cash ratio increased by 23.7% year-over-year, from 0.4× to 0.5×.
What is the long-term trend for Ultragenyx Pharmaceutical's cash ratio?
Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's cash ratio has grown at a -21.9% compound annual growth rate (CAGR), from 3.8× to 1.1×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.